Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/1004188]Researchers: Prof Peter Gunning (Principal investigator) , Dr Justine Stehn
Brief description Australia has the highest incidence of melanoma worldwide. There is a clear need to develop new strategies as melanoma is unresponsive to current treatment regimes. We have developed a compound, TR100, which targets a specific component of the cytoskeleton of melanoma tumour cells. Disruption of this cytoskeleton leads to decreased tumour cell growth and survival. Understanding the mechanism by which TR100 causes cell death is important if this novel anti-cancer compound is to be used in the clinic.
Funding Amount $AUD 578,351.99
Funding Scheme NHMRC Project Grants
Notes Standard Project Grant
- nhmrc : 1004188
- PURL : https://purl.org/au-research/grants/nhmrc/1004188
